Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Yeast strains isolated from the oropharynx of 87 consecutive patients infected with human immunodeficiency virus type 1 were examined for in vitro susceptibility to fluconazole. Candida albicans was isolated from 73 patients. Fifty-one patients had received antifungal therapy in the month preceding the yeast infection. Thirty-two patients had symptomatic oropharyngeal candidiasis. The MICs were correlated with azole use and with clinical symptoms and signs. Although there is overlap between groups, in vitro testing identified a large group of patients for whose yeast isolates the fluconazole MICs were high and who remained symptomatic while receiving azole therapy. This study supports the ability of in vitro testing to predict the clinical outcome of mucosal fungal infections. The study also demonstrates that azole resistance of oropharyngeal yeasts is a common problem in patients infected with human immunodeficiency virus type 1 and that this azole resistance has clinical relevance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937 · cited 2×
“albicans yeasts in patients receiving azoles, as have been found in other immunocompromised patients receiving fluconazole therapy (1, 7, 11, 20, 31).”
Background
Cited by
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans
Mitchell, T. G., & Perfect, J. R. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.515 · Cited by 1,213
Self-citationResistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758
Oral Azole Drugs as Systemic Antifungal Therapy
Wood, A. J. J., Como, J. A., & Dismukes, W. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300407 · Cited by 596
Antifungal susceptibility testing
Rex, J. H., Pfaller, M. A., Rinaldi, M. G., Polak, A., & Galgiani, J. N. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.4.367 · Cited by 361
Powderly, W. G., Finkelstein, D. M., Feinberg, J., Frame, P., He, W., van der Horst, C., Koletar, S. L., Eyster, M. E., Carey, J., Waskin, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503163321102 · Cited by 318
Self-citationReturn to the Past: The Case for Antibody-Based Therapies in Infectious Diseases
Casadevall, A., & Scharff, M. D. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.1.150 · Cited by 318
Rex, J. H., Pfaller, M. A., Barry, A. L., Nelson, P. W., & Webb, C. D. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.40 · Cited by 301
Pfaller, M. A., Diekema, D. J., & Sheehan, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.435-447.2006 · Cited by 295
Molecular mechanisms of drug resistance in fungi
Vanden Bossche, H., Marichal, P., & Odds, F. C. (1994) · Trends in Microbiology · doi:10.1016/0966-842x(94)90618-1 · Cited by 254
Antifungal Resistance Trends Towards the Year 2000: Implications for Therapy and New Approaches
Alexander, B. D., & Perfect, J. R. (1997) · Drugs · doi:10.2165/00003495-199754050-00002 · Cited by 153
Self-citationWhite, M. H. (1997) · Clinical Infectious Diseases · doi:10.1086/513661 · Cited by 151
Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., & Patterson, T. F. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.1.153-156.1998 · Cited by 133
White, T., Pfaller, M., Rinaldi, M., Smith, J., & Redding, S. (1997) · Oral Diseases · doi:10.1111/j.1601-0825.1997.tb00336.x · Cited by 107
Nettleman, M. D., Chen, Y.-C., Chang, S.-C., Sun, C.-C., Yang, L.-S., Hsieh, W.-C., & Luh, K.-T. (1997) · Infection Control & Hospital Epidemiology · doi:10.1086/647628 · Cited by 88
Koc, A. N., Silici, S., Ercal, B. D., Kasap, F., Hörmet-Öz, H. T., & Mavus-Buldu, H. (2009) · Medical Mycology · doi:10.3109/13693780802572554 · Cited by 61
Martins, M. D., Lozano‐Chiu, M., & Rex, J. H. (1997) · Clinical Infectious Diseases · doi:10.1086/515554 · Cited by 54
“Recently, however, a growing number of fungal isolates for which MICs of fluconazole are high have been recovered from patients with recurrent disease [6-10].”
Background
Metadata
- Authors
- Cameron, M. L., Schell, W. A., Bruch, S., Bartlett, J. A., Waskin, H. A., & Perfect, J. R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1993-11
- Volume
- 37
- Issue
- 11
- Pages
- 2449-2453
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1984491606
- Cited by
- 152
- References
- 1
- FWCI
- 23.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.